Biolife stock.

Nov 30, 2023 · See the latest BioLife Solutions Inc stock price (BLFS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Aug 9, 2023 · What really drove the stock down was BioLife's guidance. Management now expects yearly revenue to be between $144 million and $158 million, meaning a drop of between 2% and 11% over 2022. Mar 23, 2023 · Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] BioLife was founded as Trans Time Medical Products in 1987 and went public in 1989, raising net proceeds of $4.6 million at $105 per share (after giving effect to 1-for-five (2000) and 1-for-14 ...

BioLife shares outstanding (as of March 19, 2021) 33,401,359 Merger consideration percentage 19.9 % Merger consideration shares 6,646,870 less: Merger consideration shares withheld to satisfy outstanding GCI stockholder obligations to GCI 10,400 Subtotal 6,636,470 BioLife stock price (as of May 3, 2021) $ 35.07 Value of issued shares $ …BOTHELL, Wash., Sept. 1, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has closed its acquisition of Sexton Biotechnologies.

Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. ... The BLFS stock price is -102.94% off its 52-week high ...WebBioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling. BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million , with total 2021 revenue of $101 million to $110 million .

The stock information provided is for informational purposes only and is not intended for trading purposes. BioLife Sciences is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors.WebNov 3, 2023 · Bothell-based cold storage company BioLife Solutions Inc. (Nasdaq: BLFS) has raised $10.4 million through a private placement to New York City-based investment firm Casdin Capital. BioLife Sciences Inc. (“BioLife" or the "Company") (OTCPK: BLFE) specializes in moving innovative products from the lab or small-scale production. BLFE : 0.0001 (unch) BioLife Sciences Retains GS Whitney & Co for Corporate Relations Globe Newswire - Wed Aug 3, 2022. HENDERSON, NV, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioLife ...BIOLYTE® is the only Medical Grade Hydration drink to have the same amount of electrolytes as an IV bag. Our liquid IV helps fight nausea, headaches and fatigue associated with dehydration. With 6.5x more electrolytes than leading sports drinks, BIOLYTE is family owned and on a mission to help people feel better fast.The stock information provided is for informational purposes only and is not intended for trading purposes. BioLife Sciences is a commercialization accelerator, licensor and developer of innovative and disruptive technologies for the healthcare, beauty and food and beverage industry sectors.

BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...

BOTHELL, WA— January 12, 2015 — BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues (“BioLife” or the “Company”), today announced preliminary revenue for the fourth quarter …

HENDERSON, NV, June 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioLife Sciences Inc. (OTC: BLFE) (the “Company” or “BioLife”), announced today that... OTC.VN : 0.345 (unch) BLFE : 0.0001 (unch) BioLife Sciences Inc. (OTC: Markets: BLFE) Announced Today that the Company has Introduced Copper Infused Gardening Gloves to its Newly ...Stock Information; Investor Contact; Investor Contact. Media & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 ... BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA. T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 E [email protected]. NAVIGATION.WebBioLife Solutions NasdaqCM:BLFS Stock Report Last Price US$12.37 Market Cap US$563.5m 7D -8.8% 1Y -43.4% Updated 30 Nov, 2023 Data Company …In today’s fast-paced world, it can be challenging to stay organized and manage our time effectively. With so many tasks and responsibilities vying for our attention, it’s crucial to have a reliable tool that can help us stay on track. This...Get the latest Biolife Sciences Inc (BLFE) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Water bath, 37°C CryoStor CD10 (BioLife Solutions, 210102) Scalpel Surgical forceps, scissors ... 6. Add 10uL DNAse I (50mg/mL stock) to each C tube for final 100ug/mL. 7. Add 100uL Liberase TL (stock 5mg/mL) to each tube, for final 100ug/mL 8. Macerate the tissues with gentleMACS using the program m_Spleen 04.01.The estimated total pay for a Plasma Center Manager at Biolife Plasma Services is $54,580 per year. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. ... Additional pay could include bonus, stock, commission, profit sharing …

Nov 30, 2023 · BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. Congenital TTP is a life-threatening, rare genetic disorder with debilitating chronic symptoms. Find the latest Takeda Pharmaceutical Company Limited (TAK) stock quote, history, news and other ...Biolife Solutions fundamental comparison: Return On Equity vs Debt to EquityAug 8, 2023 · BioLife Solutions, Inc. (BLFS) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $1.71 per share a year ago. The BioLife Solutions stock price fell by -6.21% on the last day (Wednesday, 18th Oct 2023) from $12.39 to $11.62. During the last trading day the stock fluctuated 5.35% from a day low at $11.59 to a day high of $12.21. The price has fallen in 5 of the last 10 days and is down by -14.5% for this period. Volume fell on the last day along with ...

May 10, 2023 · BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ... BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.

Sitemap. A high-level overview of BioLife Solutions, Inc. (BLFS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …Find the latest BioLife Sciences Inc. (BLFE) stock quote, history, news and other vital information to help you with your stock trading and investing.Biolife Solutions story: Exercise or conversion by Aby Mathew of 8854 shares of Biolife Solutions subject to Rule 16b 3 and other headlines for Biolife SolutionsTrack Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsThe healthcare company's stock closed last week at $19.22, then dropped to a 52-week low of $11.82 on Friday. The stock is down more than 34% so far this year. ... So what. BioLife is a cell- and ...WebGirschweiler sold shares of BioLife stock valued at about $36 million to Casdin Capital LLC in a private transaction, the filing stated. His shares represented a 5% ownership of the BioLife.BioLife Solutions (BLFS) In a report released today, Robert Wasserman from Benchmark Co. maintained a Hold rating on BioLife Solutions. The company’s shares closed last Thursday at $11.96.WebBOTHELL, Wash., Aug. 9, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the broader biopharma market, today announced that it has entered into a definitive agreement to acquire all …WebBIOLIFE4D IPO Registration Document (S-1) BIOLIFE4D has filed to go public with an IPO on the NASDAQ. 1 year ago - SEC. Get the latest BioLife4D Corporation (SAVU) stock price quote with news, financials, IPO details and other important investing information.

Cold Chain Logistics Stocks: BioLife vs Cryoport. Regenerative Medicine. September 20. 2022. 9 mins read. A few months ago, we held a cage match between two of the leading gene-editing stocks. Basically, it ended in a draw, leaving us with a mini portfolio in this potentially lucrative but extremely volatile life sciences /nanotech market.

The stock was lifted by positive investor sentiment towards pharma companies. Investors are eagerly awaiting Biolife’s Q4 and full-year results due soon. Biolife Sciences Inc (OTCMRKTS: BLFE) stock rallied 14.2% despite not making significant announcements in a move primarily driven by positive retail investor sentiment that lifted …

Stock Information; Investor Contact; Investor Contact. Media & Investor Relations: Troy Wichterman Chief Financial Officer (425) 402 - 1400 ... BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell, WA 98021 USA. T +1.866.424.6543 or 425.402.1400 F +1.425.402.1433 E [email protected]. NAVIGATION.WebIn today’s fast-paced world, personal health tracking has become increasingly important. With the rise of digital technology, there are now numerous apps available to help individuals monitor and improve their well-being.BioLife Sciences Inc. (BLFE) is a biotechnology company that develops and commercializes products based on copper-infused microfiber and wall planters. The …Get the latest BioLife Solutions, Inc. (BLFS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the company's …BioLife Solutions NasdaqCM:BLFS Stock Report Last Price US$12.37 Market Cap US$563.5m 7D -8.8% 1Y -43.4% Updated 30 Nov, 2023 Data Company …Find the latest BioLife Sciences Inc. (BLFE) stock quote, history, news and other vital information to help you with your stock trading and investing. Biolife Solutions stocks price quote with latest real-time prices, charts, financials, latest news, ... Do the numbers hold clues to what lies ahead for the stock? BLFS: 20.37 ( …Historical daily share price chart and data for BioLife Solutions since 1992 adjusted for splits and dividends. The latest closing stock price for BioLife Solutions as of December 01, 2023 is 13.25.. The all-time high BioLife Solutions stock closing price was 140.00 on December 15, 1992.; The BioLife Solutions 52-week high stock price is 26.89, which is 102.9% …WebNov 8, 2023 · Biolife Solutions releases figures for Q3 on November 9. Wall Street analysts predict losses per share of $0.364. Go here to track Biolife Solutions stock price in real-time ahead of earnings. B. Riley FBR analyst Marc Wiesenberger resumed coverage of BioLife stock with a Buy rating and a price target of $27 per share, representing a 94.6% premium to Thursday's closing price. As cell ...

Evogene Ltd. -0.32%. $32.76M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Oct 16, 2023 · BioLife Solutions Reports First Quarter 2022 Financial Results. Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 milli... 1 year ago - PRNewsWire. BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.Instagram:https://instagram. what is a penny stock brokercoinrule reviewliberty dollar coinsuncirculated kennedy half dollars 1964 value As part of the agreement announced Monday, BioLife will acquire the remaining 56 percent of privately held SAVSU Technologies in exchange for 1.1 million shares of BioLife stock (Nasdaq: BLFS ... beach barronyield calculator Current. N/A. 1 Month Ago. N/A. 3 Months Ago. N/A. BioLife Sciences Inc. analyst estimates, including BLFE earnings per share estimates and analyst recommendations. satori fund performance 0001354488-12-003014.txt : 20120601 0001354488-12-003014.hdr.sgml : 20120601 20120601150827 accession number: 0001354488-12-003014 conformed submission type: 8-k public document count: 2 conformed period of report: 20120530 item information: entry into a material definitive agreement item information: other events item information: financial …The BioLife Solutions stock price gained 3.76% on the last trading day (Friday, 24th Nov 2023), rising from $13.57 to $14.08. During the last trading day the stock fluctuated 11.10% from a day low at $12.79 to a day high of $14.21. The price has risen in 6 of the last 10 days and is up by 23.62% over the past 2 weeks.WebB. Riley FBR analyst Marc Wiesenberger resumed coverage of BioLife stock with a Buy rating and a price target of $27 per share, representing a 94.6% premium to Thursday's closing price. As cell ...